Key facts
- Smartlens’s last known valuation is $20.0M (Apr 2023).
- It has raised $11.3M; the latest was Later Stage VC ($20.0M) in Oct 2026.
- Notable investors include Wilson Sonsini Goodrich & Rosati, 3E Bioventures Capital, Stanford University Venture Fund, Ambit Health Ventures, Boutique Venture Partners — 11 tracked in total.
- 1 investment vehicle was formed to buy Smartlens shares in the last 12 months, reporting $700K sold to 10 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Smartlens
- ·The full record, as it builds
Funding rounds
No funding rounds for Smartlens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Smartlens shares, reporting $700K sold to 10 investors. Most recent filing Sep 2025. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Smartlens
Developer of a smart contact lens platform designed to monitor intraocular pressure and prevent the progression of glaucoma and irreversible blindness. The company offers an electronics-free microfluidic contact lens paired with an AI-assisted smartphone imaging system, enabling ophthalmologists and glaucoma patients to monitor eye pressure outside clinical settings for earlier detection and management of eye disease.
- Sector
- Healthcare
- HQ
- Sunnyvale, CA, United States
- Founded
- 2015
- Employees
- 15
- Website
- smartlens.health/
- Ownership
- Privately Held (backing)
Smartlens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Smartlens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Smartlens in its N-PORT filings yet. We sweep new filings monthly.